Introduction {#s1}
============

The formation of a functional four-chambered heart is a complex process and perturbations in its development can lead to congenital heart defects (CHD). These affect almost 1% of the population and are a major cause of morbidity and infant mortality ([@bib15]). The chance of being born with CHD is drastically increased (to \~50%) in DS ([@bib49]) in which a range of heart defects is seen, including ventricular septal defects (VSD) and outflow tract abnormalities such as overriding aorta (OA) and double outlet right ventricle (DORV). Notably, defects that affect the atrioventricular (AV) junction, especially atrio-ventricular septal defects (AVSD) ([@bib16]) are often seen in DS. AVSD comprise a spectrum of cardiac malformations characterized by a common AV junction, guarded by an essentially common valve, as opposed to separate AV junctions guarded by mitral and tricuspid valves. People diagnosed with AVSD can present with communication between left and right heart chambers (shunting) at the atrial level (ostium primum defect) or at the ventricular level or with shunting at both atrial and ventricular levels ([@bib30]).

The process of forming the AV junction that divides the embryonic heart into a four-chambered structure involves the growth and fusion of a number of tissues from different precursor populations ([@bib50]). These include the atrial and ventricular septa (mainly of myocardial origin), the mesenchymal cap of the atrial septum, and the superior and inferior endocardial cushions (endocardial origin). In addition, the dorsal mesenchymal protrusion (DMP) first described as the 'spina vestibuli' by Wilhelm His the elder in 1880 ([@bib20]; [@bib33]) makes an important contribution to septation of the AV junction ([@bib2]; [@bib42]; [@bib43]; [@bib50]). The DMP is a mesenchymal structure at the venous pole of the developing heart derived from the second heart field (SHF) and perturbations of its development result in AVSD ([@bib8]; [@bib18]; [@bib38]; [@bib48]; [@bib51]; [@bib53]). Abnormalities in the DMP have also been detected in human fetal hearts with trisomy 21, leading to the hypothesis that malformation of this tissue causes the AVSD in DS ([@bib5]).

Hsa21 carries 233 protein-coding genes (genome assembly GRCh38.p5) and it is thought that DS phenotypes result from an increased dosage of one or more of the genes on Hsa21. The search for dosage-sensitive genes that when present in 3 copies cause DS phenotypes has been approached using both human and mouse genetics. In humans, rare cases of partial trisomy 21 have been used to identify critical regions that contain dosage-sensitive genes that when present in 3 copies cause DS phenotypes ([@bib12]; [@bib21]; [@bib22]; [@bib28]). Alternatively, mouse strains have been generated to study the pathology and genetics of DS.

Hsa21 shares synteny with a large region on mouse chromosome 16 (Mmu16) and with shorter regions on Mmu10 and Mmu17. The first two DS models generated, Ts65Dn ([@bib11]) and Ts1Cje ([@bib40]) have duplications of regions of mouse chromosome 16 (Mmu16) that are orthologous to Hsa21, and have been used to identify dosage-sensitive genes contributing to some DS phenotypes ([@bib3]; [@bib10]; [@bib23]; [@bib41]; [@bib46]). However, both models also have additional aneuploidy (trisomy of 60 genes on Mmu17 in Ts65Dn and monosomy of 7 genes on Mmu12 in Ts1Cje mice), making interpretation of their phenotypes difficult ([@bib13]). Another DS model, the Tc1 mouse, carries a freely-segregating copy of Hsa21 and shows many DS phenotypes, including CHD ([@bib14]; [@bib34]), although the Hsa21 in this strain is not intact and the mice are mosaic for the human chromosome, again making interpretation difficult ([@bib19]). Thanks to recent advances in chromosome engineering, a number of mouse strains with duplications of regions of mouse chromosomes orthologous to Hsa21 have been generated, resulting in partial trisomies, including the most complete mouse model for DS to date (Dp(16)1Yey/+;Dp(17)1Yey/+;Dp(10)1Yey/+), which carries a duplication of all Hsa21-orthologous regions on Mmu16, Mmu17 and Mmu10 ([@bib6]; [@bib24]; [@bib27]; [@bib26]; [@bib35]; [@bib36]; [@bib54]). However, a comprehensive mapping panel to finely map dosage-sensitive genes in DS has not been available until now.

To identify dosage-sensitive critical regions and candidate genes, we now report the generation of a fine mapping panel of 7 partial trisomies of Mmu16 that can be used to identify the genetic basis of DS phenotypes where such genes reside in the region of Mmu16 orthologous to Hsa21. We use this panel to investigate the cardiac defects in DS, employing high-resolution episcopic microscopy (HREM) to analyze the precise three-dimensional (3D) morphology of the developing hearts. This combined approach enabled us to narrow down the critical region for CHD in DS to a minimal region containing 39 protein-coding genes and to show that this region contains at least two dosage-sensitive loci required in three copies to cause CHD. Furthermore using dual-wavelength HREM we show that the DMP develops normally in these DS models, and conclude that CHD in these DS models are not caused by failure in formation or growth of the DMP.

Results {#s2}
=======

A mouse genetic mapping panel for DS {#s2-1}
------------------------------------

To expedite the identification of dosage-sensitive genes required in 3 copies to cause DS phenotypes, we generated a novel high-resolution 'mapping panel' of 7 strains with duplications in Mmu16 ([Figure 1a](#fig1){ref-type="fig"}). Of the protein-coding genes on Hsa21 that have orthologues in the mouse, the largest fraction (\~58%) is located in the telomeric region of Mmu16. Thus we used long-range Cre/loxP mediated recombination to engineer the Dp1Tyb mouse strain carrying a duplication from *Lipi* to *Zbtb21* on Mmu16 spanning 23 Mb and 148 coding genes. We then generated 3 further strains with contiguous segmental duplications completely covering the region duplicated in Dp1Tyb: Dp9Tyb (from *Lipi* to *Hunk*), Dp2Tyb (from *Mis18a* to *Runx1*) and Dp3Tyb (from *Mir802* to *Zbtb21*). To increase the resolution of the mapping panel further, we generated another 3 strains with duplications breaking up the telomeric region of Mmu16 into three contiguous fragments completely covering the region duplicated in the Dp3Tyb strain: Dp4Tyb (from *Mir802* to *Dscr3*), Dp5Tyb (from *Dyrk1a* to *B3galt5*) and Dp6Tyb (from *Igsf5* to *Zbtb21*).

![Generation of a mouse mapping panel of partial trisomies for DS phenotypes.\
(**a**) Representation of Hsa21 and the regions of conserved synteny with orthologous regions on Mmu10, Mmu17 and Mmu16 (grey lines), indicating the coordinates of each mouse region. Diagram of Hsa21 shows the main cytogenetic bands (rectangles of different colors) and the centromere (oval). Black lines show the extent of the duplication in each of the mouse strains reported here, indicating the first and last genes at the ends of each duplication. The number of genes and extent in Megabases (Mb) of each duplicated region was calculated as described in Methods (**b**) CGH analysis of each duplication strain (2 mice analyzed/strain). Plots show log2-transformed hybridization ratios for DNA from each duplication strain versus C57BL/6JNimr. The duplicated regions would be expected to have a 1.5-fold increase in DNA content (log2 ratio = 0.58).](elife-11614-fig1){#fig1}

We recovered live mutant mice from all 7 strains but noted that the yield of Dp1Tyb and Dp3Tyb mice was significantly reduced by 50% and 25% respectively ([Table 1](#table1){ref-type="table"}). We also observed hydrocephalus in Dp1Tyb mice around the time of weaning, but not in any other strain (not shown). Comparative genome hybridization (CGH) confirmed the expected copy number increase (from 2 to 3) across the duplicated regions of Mmu16 in all 7 strains, with no other copy number changes seen in the genome ([Figure 1b](#fig1){ref-type="fig"} and data not shown). These new strains provide a unique resource to study DS-associated phenotypes and to map dosage-sensitive genes causing these phenotypes.

###### Yields of wild-type (WT) and mutant mice from the 7 duplication strains.

Table shows the numbers and percentages of wild-type and mutant mice recovered at weaning (\~3 weeks old) from each of the 7 duplication strains which were bred by crossing a mutant mouse with a C57BL/6JNimr mouse. The numbers were tested for significant difference from the expected Mendelian yields (wild-type:mutant, 50%:50%) using a 2-tailed Fisher's exact test and p-values are reported in the final column where these were \<0.05, otherwise are indicated as not significant (ns).

           Mouse numbers   Percentages                     
  -------- --------------- ------------- -------- -------- ----------
  Strain   WT              Mutant        WT       Mutant   p-value
  Dp1Tyb   427             208           67.24%   32.76%   \<0.0001
  Dp2Tyb   305             253           54.66%   45.34%   ns
  Dp3Tyb   223             165           57.47%   42.53%   0.0437
  Dp4Tyb   101             78            56.42%   43.58%   ns
  Dp5Tyb   99              74            57.23%   42.77%   ns
  Dp6Tyb   191             157           54.89%   45.11%   ns
  Dp9Tyb   97              91            51.60%   48.40%   ns

Dp1Tyb mice show cardiac defects similar to those seen in DS {#s2-2}
------------------------------------------------------------

To investigate whether duplication of the region of Mmu16 from *Lipi* to *Zbtb21* in the Dp1Tyb strain was sufficient to cause CHD, we used HREM and 3D modeling ([@bib52]), an approach we had previously used successfully to identify CHD in the Tc1 strain ([@bib14]). These methods are particularly suited to examination of complex 3D structures, such as the developing heart, overcoming limitations of conventional 2D histological methods. We observed a significant increase of CHD in E14.5 Dp1Tyb embryos compared to their wild-type (Wt) littermates ([Figure 2a](#fig2){ref-type="fig"}). Detailed examination of heart morphology in the mutant embryos revealed a range of defects ([Table 2](#table2){ref-type="table"}). About 18% of Dp1Tyb hearts show abnormal arterial trunk arrangements such as OA or DORV with subaortic communication and 62% had a VSD either alone or in combination with other defects ([Figure 2b,c](#fig2){ref-type="fig"} and [Videos 1](#media1){ref-type="video"} and [2](#media2){ref-type="video"}). Two subtypes of VSD were observed: perimembranous VSD (pVSD), located in the membranous portion of the ventricular septum and muscular or trabecular VSD (mVSD), which opens to the inlet of the right ventricle ([Figure 2c](#fig2){ref-type="fig"} and [Videos 3](#media3){ref-type="video"} and [4](#media4){ref-type="video"}). Around 25% of Dp1Tyb embryos displayed AVSD presenting two bridging leaflets across the single AV junction and an 'unwedged' morphology of the left outflow tract ([Figure 2c](#fig2){ref-type="fig"} and [Video 5](#media5){ref-type="video"}). Notably, the AVSD in Dp1Tyb mice were associated exclusively with a ventricular shunt and never with an atrial shunt ([Video 6](#media6){ref-type="video"}). Thus Dp1Tyb model a subtype of AVSD with a ventricular component, in which the cushions are attached to the leading edge of the atrial septum. Overall, these data show that the Dp1Tyb mouse models the main types of CHD seen in DS.

![Dp1Tyb mice recapitulate the CHD seen in DS.\
(**a**) Graph shows the percentage of CHD in Dp1Tyb embryonic hearts at E14.5 compared to wild-type (Wt) littermates; n = 26 Wt and 39 Dp1Tyb embryos. Significant difference to corresponding wild-type incidence (Fisher's exact test) \*p\<0.05. (**b**) 3D HREM rendering of Wt and Dp1Tyb hearts, eroded from anterior to posterior to show the four-chamber view in 3 successive planes. Outflow tract defects such as double outlet right ventricle are observed in Dp1Tyb hearts (red arrow head indicates the aortic valve connecting to the right ventricle). (**c**) 3D reconstructions of Wt and Dp1Tyb E14.5 hearts with different types of CHD (red arrowheads): perimembranous ventricular septal defects (pVSD), muscular ventricular septal defect (mVSD), atrio-ventricular septal defect (AVSD). Ao, aorta; AoV, aortic valve; iAVC, inferior atrio-ventricular cushion; LV, left ventricle; MV, mitral valve; PT, pulmonary trunk; RV, right ventricle; sAVC, superior atrio-ventricular cushion; TV, tricuspid valve; VS, ventricular septum.](elife-11614-fig2){#fig2}

###### Cardiovascular abnormalities in E14.5 embryos.

Table shows the numbers of different cardiac defects found in embryos from the indicated duplication strains and in Wt littermate controls.

  --------------------- ---------------- ------ ----- ----- ------ ------ ------ ------ ------ ------ ---- ------ ------ ------ ------ ------ --- ---
  Single defects        Septal defects   ASD    1     0     0      0      0      0      1      0      0    0      0      0      0      0      0   0
  pVSD                  3                9      0     1     2      5      2      0      4      1      0    4      1      1      4      1          
  mVSD                  0                0      1     0     0      2      0      4      0      0      0    0      0      0      2      1          
  OFT defects           OA               0      0     0     0      0      0      0      0      0      0    0      0      0      0      0      0   
  DORV                  0                0      0     0     0      0      0      0      0      0      0    0      0      0      0      0          
  AVSD                  0                1      0     0     0      0      0      0      0      0      0    0      0      0      0      0          
  Multiple defects      OFT + VSD        1      2     0     0      0      1      0      0      0      0    0      0      2      0      0      0   
  pVSD + mVSD           1                3      0     0     0      1      0      0      0      2      0    0      0      0      0      0          
  VSD + AVSD            1                4      0     0     0      0      0      6      1      2      0    0      0      1      0      0          
  OFT + VSD + AVSD      0                5      0     0     0      0      0      1      0      0      0    0      0      1      0      0          
  Total number of CHD   7                24     1     1     2      9      3      11     5      5      0    4      3      3      6      2          
  Embryos analyzed      26               39     22    17    16     26     26     25     20     21     15   19     11     20     28     19         
  \% of CHD             26.9             61.5   4.5   5.9   12.5   34.6   11.5   44.0   25.0   23.8   0    21.0   27.2   15.0   21.4   10.5       
  --------------------- ---------------- ------ ----- ----- ------ ------ ------ ------ ------ ------ ---- ------ ------ ------ ------ ------ --- ---

###### OA in an E14.5 Dp1Tyb heart.

At the start of the video an image of the whole heart is seen and as it zooms in the frontal erosion of the heart reveals the four-chamber view. The pulmonary valves are seen at 00:05, coming from the right ventricle and at 00:08 the aorta is seen positioned directly over a VSD.

###### DORV in an E14.5 Dp1Tyb heart.

The video starts with an image of the whole heart and frontal erosion reveals that the aorta is communicating with the right ventricle (00:04). The video then zooms in to reveal in more detail how the aortic valves are communicate with the right ventricle. Further erosion also shows a VSD at the end of the video (00:17).

###### pVSD in an E14.5 Dp1Tyb heart.

At the start the video shows the whole heart and then erodes frontally to show a pVSD (00:08). The video then erodes slightly further to show the connection of the ventricular septum with the endocardial cushions. The image then zooms in and erodes backwards to show the pVSD at higher magnification.

###### mVSD in an E14.5 Dp1Tyb heart.

The video shows a whole heart that rotates to view the apex of the ventricles and then erodes transversally revealing the ventricular septum. The mVSD is first seen at 00:08 and the image then zooms in to show it at higher magnification.

###### AVSD in an E14.5 Dp1Tyb heart.

The video shows a whole heart that rotates to view the apex of the ventricles and then erodes upwards. The bridging leaflets across the common AV junction can first be seen at 00:05, but they are more clearly visible as the heart is eroded further and a close look at the AV valves is shown at the end of the video (00:16), where the superior and inferior bridging leaflets forms a common AV junction. Note the "unwedged" morphology of the left outflow tract on top of the superior bridging leaflet.

###### AVSD with intact DMP in an E14.5 Dp1Tyb heart.

The video shows the whole heart that initially erodes transversally from the apex to reveal an AVSD (00:03 to 00:07). The heart is then reconstructed and eroded frontally to show a pVSD (00:13). Further erosion shows an intact DMP on top of the endocardial cushions (00:13 to 00:17). Note this is the same heart as shown in [Video 5](#media5){ref-type="video"}.

CHD mapped to at least 2 loci in a 4.9 Mb telomeric region of Mmu16 {#s2-3}
-------------------------------------------------------------------

To identify the critical region(s) sufficient to cause CHD in DS, we examined heart development in Dp9Tyb, Dp2Tyb and Dp3Tyb mice that between them have duplications covering the entire duplicated region in Dp1Tyb mice ([Figure 1a](#fig1){ref-type="fig"}). HREM analysis of embryonic hearts at E14.5 revealed that neither Dp9Tyb nor Dp2Tyb showed a significant increase of CHD compared to Wt littermates ([Figure 3a](#fig3){ref-type="fig"}). In contrast, the telomeric duplication of 39 coding genes in the Dp3Tyb strain was sufficient to cause a significant increase in embryos with CHD. We observed VSD such as pVSD, mVSD in the inlet portion of the ventricular septum, as well as AVSD ([Figure 3b](#fig3){ref-type="fig"}, [Table 2](#table2){ref-type="table"} and [Videos 7](#media7){ref-type="video"} and [8](#media8){ref-type="video"}). We noted a reduced frequency of outflow tract defects in Dp3Tyb embryos compared to Dp1Tyb, however this difference was not statistically significant. Overall the types of defects observed in Dp3Tyb were very similar in both type and severity to the ones in Dp1Tyb mice, suggesting that all the dosage-sensitive gene(s) required to cause CHD in Dp1Tyb mice were located in this shorter region.

![Genetic dissection of DS-associated CHD.\
(**a**) Representation of Hsa21 showing region of conserved synteny with Mmu16 in grey and the extent of the duplications in Dp9Tyb, Dp2Tyb and Dp3Tyb in black. Graphs show the incidence of CHD in each strain; n = 22 Wt, 17 Dp9Tyb; n = 16 Wt, 26 Dp2Tyb and n = 26 Wt, 25 Dp3Tyb embryos. Significant difference to corresponding wild-type incidence (Fisher's exact test) \**P*\<0.05. ns, not significant. (**b**) 3D reconstructions of Wt and Dp3Tyb E14.5 hearts with different types of CHD (red arrowheads) as described in [Figure 2c](#fig2){ref-type="fig"}. (**c**) Representation of Hsa21 showing region of conserved synteny with Mmu16 in grey and the extent of the duplications in the indicated strains in black. Graphs shows incidence of CHD. n = 20 Wt, 21 Ts1Rhr; n = 15 Wt, 19 Dp4Tyb; n = 11 Wt, 20 Dp5Tyb and n = 28 Wt, 19 Dp6Tyb embryos analyzed. ns, not significant (Fisher's exact test). iAVC, inferior atrio-ventricular cushion; LV, left ventricle; MV, mitral valve; RV, right ventricle; sAVC, superior atrio-ventricular cushion; TV, tricuspid valve; VS, ventricular septum.](elife-11614-fig3){#fig3}

###### mVSD in an E14.5 Dp3Tyb heart.

The embryonic heart is eroded upwards from the apex of the ventricles to reveal an mVSD in the inlet portion of the ventricular septum (00:17).

###### AVSD in an E14.5 Dp3Tyb heart.

The heart is first eroded frontally to show a pVSD (00:04). The heart is then reconstructed and eroded from the top of the OFT downwards to reveal an AVSD (00:13 to 00:17).

To further narrow down the critical region for CHD, we analyzed embryonic hearts from the Ts1Rhr strain, which has a duplication that is shorter than that in the Dp3Tyb strain by just 8 genes (7 coding genes and 1 micro-RNA gene) ([@bib35]). We and others have previously reported that this strain does not show CHD ([@bib14]; [@bib26]). However, in our earlier study we had examined Ts1Rhr on the mixed 129S8;C57BL/6JNimr genetic background, whilst Dp1Tyb and Dp3Tyb are maintained on the C57BL/6JNimr background. Thus in order to eliminate possible confounding effects of background differences, we backcrossed Ts1Rhr to the C57BL/6JNimr background and used HREM to look for CHD. Once again we found no increased frequency of CHD in the Ts1Rhr strain ([Figure 3c](#fig3){ref-type="fig"}). Thus an extra copy of one or more of the 8 genes duplicated in Dp3Tyb but not in Ts1Rhr is required to cause CHD. Next we analyzed Dp4Tyb, Dp5Tyb and Dp6Tyb mice each of which carry a duplication that between them cover the whole of the duplicated region in Dp3Tyb mice. Remarkably, none of these 3 strains showed significant increased rates of CHDs indicating that there are at least two dosage-sensitive loci in the Dp3Tyb mouse that contribute to CHD ([Figure 3c](#fig3){ref-type="fig"}).

Taken together these data show that a 4.9 Mb region of Mmu16 from *Mir802* to *Zbtb21* is sufficient when in 3 copies to generate cardiac defects similar to those seen in DS. Furthermore, the mapping analysis shows that there are two or more loci within this region that are required in 3 copies to cause CHD, and that at least one of these resides within the 8 genes duplicated in Dp1Tyb but not Ts1Rhr mice.

Development of the DMP {#s2-4}
----------------------

The DMP plays a crucial role in the formation of the AV junction, and defects in its development have been proposed to underlie the AVSD in DS ([@bib5]; [@bib7]). In order to assess if DMP development was perturbed in the Dp1Tyb mouse model of DS, we first established a method to follow its development during formation of the AV junction. The *Isl1* gene is expressed in the SHF and also in the DMP which is derived from it and hence can be used as a marker for this tissue. We visualized expression of *Isl1* using 2 different mouse strains: the Isl1Cre ([@bib9]) strain crossed to Rosa26RLacZ reporter mice ([@bib44]) to identify cells that are expressing or had expressed *Isl1*, and thus are derived from the SHF; and the Isl1nLacZ strain ([@bib45]) to visualize ongoing expression of *Isl1*. Gene expression studies have traditionally relied on staining individual sections and rendering a 3D expression pattern by compiling histological sections, but this approach results in loss of resolution and is constrained by the chosen sectioning plane. To get around this, we utilized dual-wavelength HREM ([@bib32]) to visualize β-galactosidase expression in the 3D context of the developing heart in order to get an accurate view of the development of the DMP. At E11.5 analysis of both strains shows there is an expansion of *Isl1*-expressing mesenchymal tissue from within the right pulmonary ridge, which forms the DMP and has started to protrude ventrally into the cavity of the right atrium ([Figure 4](#fig4){ref-type="fig"}). One day later at E12.5, the DMP has protruded more ventrally and it is now in contact with the inferior atrioventricular cushion. At these stages both reporters give a similar picture, as the DMP is actively expressing *Isl1*. Later in development (E13.5) the expression of *Isl1* diminishes and totally disappears by E14.5 ([Figure 4](#fig4){ref-type="fig"}; [@bib43]). However development of the DMP can still be followed using the Isl1Cre/Rosa26RLacZ fate reporter strain. This revealed that by E14.5 the DMP forms the ventro-caudal buttress at the core of the AV junction sandwiched between the atrial septum and the endocardial cushions that have now developed into the tricuspid and mitral valves ([Figure 4](#fig4){ref-type="fig"}). Overall, using two different genetic lineage markers of the SHF, these data show a detailed 3D view of the spatio-temporal development of the DMP.

![Development of the DMP.\
Left panels show a series of 3D four-chamber views of hearts at embryonic stages E11.5, 12.5, 13.5 and 14.5. Middle panels show a close up of the AV junction (frontal plane view corresponds to blue dashed box in the left panels) in the Isl1Cre/Rosa26RLacZ (Isl1Cre) and the Isl1nLacZ strains; β--galactosidase expression is pseudo-colored in red. Right panels show a sagittal view of the AV junction in E11.5 and E12.5 hearts and a transverse view in E13.5 and E14.5 hearts; sagittal and transverse planes shown as orange dashed line in left panels; β--galactosidase expression is pseudo-colored in red. In the middle and right panels the DMP is marked with a black dashed contour. The number of biological replicates used for each of the developmental stages, E11.5, E12.5, E13.5 and E14.5 respectively, were: n = 2, 2, 6 and 4 for the Isl1Cre/Rosa26RLacZ and n = 10, 9, 7 and 5 for the Isl1nLacZ. AoV, aortic valve; AVC, atrioventricular canal; iAVC, inferior atrioventricular cushion; MV, mitral valve; RA, right atrium; TV, tricuspid valve; VS, ventricular septum. Scale bar, 200 μm.](elife-11614-fig4){#fig4}

The DMP is present and largely unaffected in the Dp1Tyb mouse model for DS {#s2-5}
--------------------------------------------------------------------------

To test whether the AVSD seen in Dp1Tyb mice are caused by defects in development of the DMP, as has been proposed, we imaged the DMP in these mice using the Isl1nLacZ reporter strain. We found that at both E11.5 and E12.5 the DMP was present in Dp1Tyb embryos at a similar location to that seen in Wt mice ([Figure 5a](#fig5){ref-type="fig"}). Volumetric analysis showed that at E11.5 in both Wt and Dp1Tyb embryos, the DMP appears rounded in shape and attached to the dorsal extracardiac mesenchyme. Furthermore, the size and shape factor of the DMP in Dp1Tyb mice was similar to that in Wt mice. At E12.5 the size of the DMP was reduced in the mutant mice, but in both strains the DMP was more elongated and showed a similar shape factor ([Figure 5a](#fig5){ref-type="fig"}).

![Largely normal development of the DMP in Dp1Tyb mice.\
(**a**) 3D reconstruction of control Isl1nLacZ and Isl1nLacZ/Dp1Tyb E11.5 and E12.5 hearts analyzed using dual filter HREM. In the first two columns heart morphology is in grey and LacZ expression is pseudo-colored in red. Left panels show a transverse view of the developing heart and middle panels show a sagittal plane at E11.5 and a 4-chamber view at E12.5. The DMP is marked with a dashed black contour. Orientation is marked with 4 arrows (A, anterior; D, dorsal; L, left; P, posterior; R, right; V, ventral). Right image panels show two representative 3D reconstructions of the DMP for control and Dp1Tyb embryos at E11.5 and E12.5; the DMP is pseudo-colored in blue and surrounding dorsal mesenchyme is pseudo-colored in yellow. Graphs show the volume and shape factor of the DMP (n = 9 Wt and 9 Dp1Tyb E11.5 embryos, n = 9 Wt and 12 Dp1Tyb E12.5 embryos). Results are presented with measurements from each heart and as mean ± s.e.m. Statistical analysis with an unpaired Student's *t*-test; ns, not significant, \**P*\<0.05. (**b**) 3D HREM rendering of hearts from a single Wt and a single Dp1Tyb embryo at E14.5. The left images show the AV junction in short axis view from the ventricles towards the atria. Red arrowheads indicate the bridging leaflets of the common AV junction in the Dp1Tyb heart. The middle images show a 4-chamber view visualizing the ventricular septum. Red arrowhead indicates a pVSD in the Dp1Tyb heart. The right images show a more dorsal plane of the 4-chamber view to visualize the DMP, marked with a red dashed contour in both Wt and Dp1Tyb hearts. iAVC, inferior atrioventricular cushion; LV, left ventricle; MV, mitral valve; OFT, outflow tract; RA, right atrium; RV, right ventricle; SAN, sinoatrial node; sAVC, superior atrioventricular cushion; TV, tricuspid valve; VS, ventricular septum. Scale bar, 50 μm.](elife-11614-fig5){#fig5}

At E11.5 and E12.5 it is not possible to identify which of the hearts would have developed AVSD, and thus we could not tell if mice with largely normal DMP development would have gone on to show defects. To evaluate this issue directly we examined E14.5 Dp1Tyb hearts with AVSD for the presence of the DMP. Once again we used HREM with 3D modeling and examined the same Wt and Dp1Tyb hearts using three different views. In a short axis view across the AV junction we saw an AVSD in the Dp1Tyb heart with the superior and inferior bridging leaflets across the single AV junction while the Wt heart showed a normal AV junction ([Figure 5b](#fig5){ref-type="fig"}, left panels). A long axis four-chamber view of the same hearts showed an intact ventricular septum in the Wt heart but a VSD in the Dp1Tyb heart ([Figure 5b](#fig5){ref-type="fig"}, middle panels). Finally, a more dorsal plane of the long axis view of the same hearts showed that the DMP was located in the correct position at the AV junction in both the Wt and the Dp1Tyb hearts ([Figure 5b](#fig5){ref-type="fig"}, right panels, and [Video 6](#media6){ref-type="video"}). We performed the same analysis on the Dp3Tyb mice and once again found that the DMP was present in embryos with AVSD (not shown). Taken together these data show that the AVSD found in these new mouse models of DS are not caused by perturbations of the growth of the DMP. Importantly, we note that defects in the DMP have been previously shown to result in atrial septal defects or AVSD with atrial shunting ([@bib7]), neither of which are seen in Dp1Tyb or Dp3Tyb mice. In contrast these strains show AVSD with exclusive ventricular shunting, implying that this subtype of AVSD must be due to defects in tissues other than the DMP.

Discussion {#s3}
==========

Cardiac abnormalities are very common in DS. Approximately half of all babies born with DS have a heart defect, many of which are serious and need to be surgically repaired. In order to understand the genetic and molecular mechanisms that lead to CHD in DS it is essential to establish mouse models for DS that accurately recapitulate them. Here we report the generation of a new mouse strain Dp1Tyb with a 23 Mb duplication of the entire region of Mmu16 orthologous to Hsa21, and show that it recapitulates the main types of CHD seen in DS. The Dp(16)1Yey mouse strain carries a similar duplication to Dp1Tyb encompassing the same set of genes and was also reported to have heart defects during embryogenesis ([@bib24]). Interestingly, the cardiac phenotypes in Dp1Tyb are very similar to the ones we previously observed in the transchromosomic strain Tc1 ([@bib14]; [@bib34]), despite differences in the Hsa21 orthologous gene content in the two strains and the different species origin for the duplicated genes: mouse in Dp1Tyb mice, human in Tc1 mice. This phenotypic similarity supports the conclusion that the CHD seen in these strains are caused by the same pathological mechanisms as those in people with DS. As with CHD in humans with DS we observed incomplete penetrance of the phenotype in Dp1Tyb mice. In humans this has been ascribed to genetic modifiers ([@bib25]). However the Dp1Tyb mouse strain was analyzed on an inbred background, suggesting that incomplete penetrance may be caused by stochastic effects during embryonic cardiogenesis. While the recovery of E14.5 Dp1Tyb embryos was consistent with expected Mendelian numbers (not shown), the recovery of Dp1Tyb mice at weaning was reduced to 50% of the expected numbers ([Table 1](#table1){ref-type="table"}). Some of this loss could be due to the most severe CHDs, since AVSDs were found in \~25% of E14.5 Dp1Tyb embryos, but it is likely that there are other unknown causes for this perinatal lethality. The other strain to show AVSDs, Dp3Tyb, showed a 25% reduction in recovery of mice at weaning, similar to the observed frequency of AVSDs at E14.5, making this a likely cause of the reduced yield of mutant mice.

Together with the Dp1Tyb strain we generated a collection of 7 new mouse strains with segmental duplications ranging from 1.5 Mb to 23 Mb that provide a genetic resource for mapping dosage-sensitive genes required in 3 copies to cause DS phenotypes. We used this mapping panel to identify a 4.9 Mb genomic region (from *Mir802* to *Zbtb21*) that when present in 3 copies is sufficient to cause CHD. Furthermore, from analysis of shorter duplications, we show that the phenotype is caused by at least two distinct dosage-sensitive loci. By combining this data with analysis of the Ts1Rhr strain, we have determined that, minimally, one of the two loci lies either in an interval at the centromeric end of the duplication in Dp3Tyb (from *Mir802* to *Setd4*) or at the telomeric end (from *Mx2* to *Zbtb21*) ([Figure 6a](#fig6){ref-type="fig"}). These two segments between them contain only 7 coding genes (*Setd4, Mx2, Tmprss2, Ripk4, Prdm15, C2cd2* and *Zbtb21*) and one microRNA gene (*Mir802*), none of which had been previously implicated in causing CHD in DS. A previous study proposed that a 3.7 Mb genomic region of Mmu16 (*Ifnar1* -- *Kcnj6*) in Dp(16)4Yey was sufficient to cause CHD ([@bib27]); this region overlaps the centromeric end of the duplicated region of Dp3Tyb by 1.9 Mb from *Mir802* to *Kcnj6*, which may help to further narrow down the search for causative genes ([Figure 6b](#fig6){ref-type="fig"}). We note that while the Dp5Tyb and Ts1Rhr strains did not show a statistically significant increase in CHDs compared to their wild-type littermate controls, in both strains we detected 2 mutant embryos with AVSDs (out of 20 or 21 embryos analyzed respectively). Thus it is possible that these strains have a weak phenotype -- a larger number of embryos from these strains would need to be analyzed to establish whether this is significant. If true, it would suggest that one or more of the causative genes may reside within the Dp5Tyb interval (which is entirely contained within the Ts1Rhr interval).

![Genetic and mechanistic dissection of CHD in mouse models of DS.\
(**a**) Representation of Hsa21 and the conserved region of synteny with the telomeric part of Mmu16 (grey line). Black lines indicate the extent of the duplications in Dp3Tyb and Ts1Rhr strains. Magnifications show the ends of the duplications indicating the 8 genes duplicated in Dp3Tyb but not Ts1Rhr mice. (**b**) Hsa21 and orthologous portion of Mmu16 (grey line), showing extent of duplication in Dp3Tyb (red line, this study) and Dp(16)4Yey (black line) ([@bib27]). Also shown are the extent of partial trisomies of two individuals with DS who had a VSD (PM) or AVSD (BA) (blue lines) ([@bib21]). (**c**) Diagrams show a normal heart (right) and 3 types of AVSD depending on the relationship of the AV valves to the septal components and the presence/absence of the DMP (red). Defects in the DMP are seen in AVSD with atrial shunting (ostium primum) or in complete AVSD with both atrial and ventricular shunts. Dp1Tyb mice have AVSD with a ventricular shunt and the DMP is present (red boxes). AS, atrial septum; DMP, dorsal mesenchymal protrusion; LA, left atrium; LV, left ventricle; MV, mitral valve; RA, right atrium; RV, right ventricle; TV, tricuspid valve; VS, ventricular septum.](elife-11614-fig6){#fig6}

In contrast, analysis of humans with partial trisomies of Hsa21 identified distinct regions that contribute to cardiac abnormalities ([@bib4]; [@bib21]). An individual (PM) trisomic for the 7.7 Mb region from *PSMG1* to *PRMT2* had a VSD, whereas the shortest partial trisomy (individual BA) that gave rise to AVSD extended 10.0Mb from *HLCS* to *PRMT2* ([Figure 6b](#fig6){ref-type="fig"}). We note that that while both of these intervals overlap substantially with the minimal Dp3Tyb region identified in our studies, the duplicated region in individual PM does not overlap at all with the *Ifnar1* -- *Kcnj6* region identified by Liu et al as being sufficient to cause CHDs ([@bib27]). In particular the human studies suggested that increased dosage of the *DSCAM* gene may be responsible for the CHDs ([@bib21]). In contrast the mouse studies show that duplication of *Dscam* is neither necessary or sufficient to cause CHDs, since the gene is not within the minimal *Ifnar1* -- *Kcnj6* region identified by Liu et al as being sufficient for CHDs ([@bib27]) but is duplicated in the Dp6Tyb strain which we show here does not have CHDs. Taking the human and mouse data together, this suggests that several dosage-sensitive genes may contribute to CHDs, with potentially no single gene being absolutely required.

Dp1Tyb mice show AVSD with ventricular but not atrial shunting. Analysis of AVSD in people with DS showed that the most common subtype was a complete AVSD with both atrial and ventricular shunting and the next most common was AVSD with exclusive ventricular shunting similar to that seen in the Dp1Tyb mouse ([@bib17]). Thus, although Dp1Tyb mice show AVSD, they only model one subtype of AVSD seen in people with DS -- AVSD with ventricular shunting. It is not known why some cases of DS have complete AVSD whereas others have subtypes with only atrial or ventricular shunting, but it is tempting to speculate that there are distinct mechanisms driving defects in the atrial and ventricular septa.

AVSD have been shown to result from defects in development of the DMP ([@bib8]; [@bib18]; [@bib38]; [@bib48]; [@bib51]; [@bib53]). Importantly, a variety of different genetic manipulations that affect the DMP all resulted in AVSD with exclusive atrial shunting, demonstrating the importance of the DMP for the correct formation of the atrial side of the AV junction ([@bib7]). In contrast, in Dp1Tyb mice we found normal DMP development and no AVSD with atrial shunting, but instead saw exclusively AVSD with ventricular shunting ([Figure 6c](#fig6){ref-type="fig"}). Thus we propose that defects in the atrial septum causing the ostium primum type of AVSD are caused by malformation of the DMP, whereas ventricular defects are due to perturbations in other tissues, such as endocardial cushions or myocardium. Interestingly, Gata4-deficient mice display AVSD and have a normal DMP, but show perturbations in myocardial signaling to the adjacent atrioventricular cushion mesenchyme, suggesting that defects in myocardial signaling could lead to AVSD ([@bib31]; [@bib37]). To our knowledge the Dp1Tyb and Dp3Tyb mouse strains are the first to have been shown to have AVSD with ventricular shunting and thus will allow direct studies of the pathological mechanisms underlying this subtype of AVSD.

In conclusion, we have generated a mapping panel of 7 mouse strains that can be used to identify dosage-sensitive genes underlying the broad range of DS phenotypes, and we have exploited this panel to map the location of genes causing CHD in DS.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

We generated ES cells with a duplication from *Lipi* to *Zbtb21* using Cre/loxP-mediated chromosome engineering ([@bib55]) following strategies similar to those previously used to make mice with duplications of Hsa21-orthologous regions ([@bib6]; [@bib24]; [@bib27]; [@bib26]; [@bib35]; [@bib36]; [@bib54]). MICER vectors ([@bib1]) MHPP352i17 (coordinates of homology region 16:74930370--16:74937378 Mb, mouse assembly GRCm38/mm10) and MHPN352i16 (16:97977263--16:97982380 Mb) were used sequentially as targeting vectors to insert loxP sites proximal to *Lipi* and distal to *Zbtb21* respectively in HM-1 ES cells ([@bib29]); the cells had been tested to be negative for mycoplasma contamination. Targeting was carried out by standard procedures. Cre recombinase was transiently expressed in double-targeted ES cells to induce recombination between the loxP sites. Segmental duplication was confirmed by Southern blot analysis, targeted clones were injected into blastocysts to generate chimeric mice and these were bred to establish the C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb) mouse strain by standard methods. ES cells with a duplication from *Mis18a* to *Runx1* were generated in the same way using MICERs MHPP323h04 (16:90563769 -- 16:90577148 Mb) and MHPN219i02 (16:93054020 -- 16:93062456 Mb) to target loxP sites proximal to *Mis18a* and distal to *Runx1* respectively, followed by Cre-mediated recombination, and correctly targeted ES cells were used to establish the C57BL/6J.129P2-Dp(16Mis18a-Runx1)2TybEmcf/Nimr (Dp2Tyb) mouse strain. For the remaining duplication strains C57BL/6J.129P2-Dp(16Mir802-Zbtb21)3TybEmcf/Nimr (Dp3Tyb), C57BL/6J.129P2-Dp(16Mir802-Dscr3)4TybEmcf/Nimr (Dp4Tyb), C57BL/6J.129P2-Dp(16Dyrk1a-B3galt5)5TybEmcf/Nimr (Dp5Tyb), C57BL/6J.129P2-Dp(16Igsf5-Zbtb21)6TybEmcf/Nimr (Dp6Tyb), and C57BL/6J.129P2-Dp(16Lipi-Hunk)9TybEmcf/Nimr (Dp9Tyb) we used an in vivo Cre-mediated recombination strategy whereby we bred female mice containing the *Hprt*^tm1(cre)Mnn^ allele ([@bib47]) and two loxP sites located in trans configuration on Mmu16 at the boundaries of the desired duplication, to C57BL/6JNimr males and Cre activity in the female germline from the *Hprt*^tm1(cre)Mnn^ allele resulted in occasional pups (0.7--6%) with recombination between the loxP sites generating the duplication. The loxP sites were derived from targeting with the 4 MICERs described above as well as MHPP432c09 (16:94538615--16:94546849 Mb) located between *Dscr3* and *Dyrk1a* and MHPN235b18 (16:96327324--16:96331804 Mb) located between *B3Galt5* and *Igsf5*.

Dp(16Cbr1-Fam3b)1Rhr (Ts1Rhr) mice ([@bib35]), *Isl1*^tm3Sev^ (Isl1nLacZ) ([@bib45]), *Isl1*^tm1(cre)Sev^ (Isl1Cre) ([@bib9]), Gt(ROSA)26Sor^tm1Sor^ (ROSA26RLacZ) ([@bib44]), *Hprt*^tm1(cre)Mnn^ and all duplication mouse strains generated above were maintained by backcrossing to C57BL/6JNimr. All mice used for experiments had been backcrossed for at least 5 generations. Specifically, Dp1Tyb was analyzed after backcrossing to C57BL/6JNimr for 6--9 generations (N6-N9), Dp2Tyb at N5, Dp3Tyb at N8, Dp4Tyb at N5-N7, Dp5Tyb at N5, Dp6Tyb at N5-N11, Dp9Tyb at N11 and Ts1Rhr at N11-N12. Genotyping was carried out using custom probes (Transnetyx). All animal work was carried out under a Project Licence granted by the UK Home Office.

Enumeration of genes {#s4-2}
--------------------

To count numbers of genes in the duplication intervals we used the Biomart feature of Ensembl (mouse genome assembly GRCm38.p4) to count numbers of genes within a given interval, filtering either for protein-coding genes or for protein-coding genes with orthology to human. In addition we included the Mx2 gene as a protein-coding gene, since Ensembl did not automatically classify this gene as coding.

Array comparative genome hybridization (aCGH) {#s4-3}
---------------------------------------------

Genomic DNA was prepared from the tail of each of the duplication strains and from C57BL/6JNimr mice to be used as a reference control using either phenol-chloroform extraction or DNeasy Blood and Tissue Kit (Qiagen, UK). DNA (1 μg) was analyzed by Roche Diagnostics Limited using a mouse 3 × 720 K array (Roche NimbleGen) or by Oxford Gene Technology using a mouse 1 × 1 M array (Agilent Technologies). 50--75 mers probes were used and the design was based on the genome assembly mm9. The hybridized aCGH slides were scanned for Cy3 (test) and Cy5 (control) channels. The Log2 ratios of the test/control were calculated and plotted as graphs using Prism 7.

HREM imaging and 3D modeling {#s4-4}
----------------------------

E14.5 embryonic hearts were dissected and fixed for 30 min in 4% paraformaldehyde followed by a 1 hr wash in distilled water and secondary fixation overnight. Fixed samples were dehydrated and embedded in modified JB4 methacrylate resin ([@bib52]) and sectioned at 2 μm. HREM imaging (isometric resolution of 2 μm) used a Hamamatsu Orca-HR camera. Data sets were normalized and subsampled prior to 3D volume rendering using Osirix v5.6 ([@bib39]). As the expected CHD were not fully penetrant, a minimum of 17 E14.5 mutant embryos were compared to littermate controls. Phenotype analysis was performed blind for genotype, and classification of type of CHD was carried out as previously described ([@bib14]). For dual-wavelength HREM, a conventional Xgal reaction was performed followed by 4% paraformaldehyde fixation, dehydration and embedding, and imaging was carried out using a Jenoptik ProgRes C14 camera with dual filter (59022bs, Chroma Technology Corp). Image analysis of the DMP was done using ITKsnap 2.4.0 and Volocity 6.2.1 software packages. Volocity was used to calculate the volume of the DMP and the shape factor (shape factor is 1 for a perfect sphere and \<1 for more irregular shapes). A minimum of 9 biological replicates per group was analyzed and analysis of the DMP was performed blind for genotype.
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Decision letter

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your work entitled \"Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Stylianos Antonarakis as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

This manuscript describes the cardiac phenotype in seven mouse strains with partial trisomies of regions of mouse chromosome 16. These morphological analyses enable the identification of a minimal critical region which, when trisomic, causes congenital heart defects. It is further reported that there are two loci within this region that are required to be trisomic for the effect on heart development. In addition, the authors use the abnormal phenotype to show that AVSD with shunting at the ventricular level can develop in the presence of a morphologically normal dorsal mesenchymal protrusion (DMP).

The reviewers appreciated the sophisticated genetic manipulations and the high quality of the morphological data. However the following points need to be addressed:

1\) In the comparison between human and mouse more discussion is required of the extent to which the studies of Down Syndrome translocation cases and the intervals defined by them match the mouse data presented here. The paper by Korbel et al. in PNAS 2009 is mentioned but the authors could be a bit clearer on the degree of genetic content overlap between the regions they define in their manuscript and the \<2-Mb DS-specific congenital heart disease (DSCHD) interval defined by Korbel.

There is a clear difference in phenotype that the authors discuss but rather underplay ("Dp1Tyb mice show AVSD with ventricular but not atrial shunting" -- "it is tempting to speculate that there are distinct mechanisms driving defects in the atrial and ventricular septa"). About 80% of Down\'s hearts with AVSD have the \"complete\" type, with shunting at atrial and ventricular level, whereas none of the hearts from mouse partial trisomies had this phenotype. The authors speculate that different mechanisms might act in the atrial and ventricular aspects of AV septal formation. If so, it could be considered that their models encompass only one of those two mechanisms.

There is no mention in the Discussion of mouse trisomy 16, which is not a good model of Down\'s-type defects for other reasons, but Ts16 hearts do have AVSD with shunting at the atrial level (Webb et al., (1999) Circ. Research 84:897-905), which is what is absent in the partial trisomy models studied here. Interestingly, Ts16 hearts do have deficiencies in DMP development.

2\) CHD are observed in 50% of people with Down Syndrome and usually necessitate cardiac surgery to avoid any late impairment. Here the results are limited to 14.5dpc embryos in which CHD and mainly AVSD are observed but little is described about the consequence of the CHD on perinatal viability. Kamp et al. (2010; PMID20511334) reported the identification of mouse congenital heart disease loci with most of them inducing perinatal lethality with CHD at birth. If the authors have data on the frequency of perinatal lethality and structural heart defects in the duplication carrier at birth, these should be included.

3\) It would be interesting to see a table with the number of individuals studied showing the different types of CHD compared to the total of embryos in the different mouse cohorts from the 7 duplication.

The authors should also discuss the variability of the CHD and AVSD phenotypes observed in wt control animals analysed from the different cohorts of mice. For example, the wt in Dp5Tyb and DP6Tyb or Ts1Rhr showed almost 20% of CHD compared to Dp9Tyb (5%?) Dp2Tyb and Dp3Tyb (10%?). What are the origins of such discrepancies in wt cohorts? A comparison of the CHD in wild-type individuals from the different cohorts, presented as a supplementary table, would add value to the analysis.

4\) The authors have done their analysis after 5 backcrosses on the C57BL/6JNimr genetic background. Could they assess if this level is sufficient in this particular situation? The presence of 2 copies of the 129S8 allele on the duplicated fragment versus the B6 allele may influence the outcome of the study (and may also explain the heterogeneity of the control littermates). Thus it would be interesting to check what is the real contribution of the B6 and 129 alleles, at least for the trisomic regions in the different models.

5\) An important point is whether by crossing strains Dp4Tyb, Dp5Tyb and Dp6Tyb, the CHD can be reconstituted to narrow further the key genetic contributions. Incomplete penetrance is commonplace in CHD and the finding that two genes require three copies to produce CHD in these models is intriguing in this context and merits further discussion.

6\) The conclusions about which regions of Dp1Tyb are required in three copies to induce Downs-type heart defects rely wholly on comparisons between some very small numbers of abnormal hearts, which are usefully summarized in Table 1. Hearts from Ts1Rhr and Dp5Tyb each had 2 AVSD (of 21 and 20 examined respectively), which is undoubtedly statistically different from the incidences in Dp1Tyb and Dp3Tyb, but it is difficult to say with certainty that there is no effect in Ts1Rhr and Dp5Tyb, particularly given that there was only 1 AVSD observed in about 170 wild type hearts. There could be a weak combinatorial effect of a number of genes throughout the region. The authors should be more cautious in the wording of their conclusions. \[One of the AVSD in Dp5Tyb did not have an ASD or VSD, an outlier which goes without explanation or mention\].

7\) For completeness, it would be useful to generate Isl1Cre lineage marked Dp1Tyb hearts, as well as the Isl1nLacZ expression (this is incorrectly termed \"lineage\" in the subsection "The DMP is present and largely unaffected in the Dp1Tyb mouse model for DS") marked hearts. It would be informative to show these data at E14.5, in definitively AVSD hearts.

10.7554/eLife.11614.sa2

Author response

> 1\) In the comparison between human and mouse more discussion is required of the extent to which the studies of Down Syndrome translocation cases and the intervals defined by them match the mouse data presented here. The paper by Korbel et al.in PNAS 2009 is mentioned but the authors could be a bit clearer on the degree of genetic content overlap between the regions they define in their manuscript and the \<2-Mb DS-specific congenital heart disease (DSCHD) interval defined by Korbel.

We have amended the Discussion to include a fuller discussion of the CHD in humans with partial trisomy of Hsa21 as evaluated by Barlow et al. (2001) and Korbel et al. (2009), comparing their conclusions to our data and that of Liu et al. (2013) in the mouse (Discussion, third paragraph). To aid in this we have added a new panel to Figure 6 (Figure 6B) showing the extent of the shortest partial trisomies in humans with DS that lead to VSD or AVSD respectively. The figure also shows the shortest duplication that leads to CHDs in the mouse as reported in the study by Liu et al. (2013).

The 1.77 Mb region reported in Korbel 2009 as being a minimal critical region for CHD was derived from a region present in all individuals with partial trisomy of Hsa21 who had CHDs which was further limited to the overlap with the orthologous region on Mmu16, since mice with a duplication of just this orthologous region have CHDs (Dp1Yey mice, Li et al. 2007). In other words, this 1.77 Mb region has been identified based on several individuals and on mouse data, and there is no known individual trisomic just for this 1.77 Mb region who has CHD. In view of this, we thought it was more useful to show the extent of trisomy in two individuals (PM and BA) reported in Korbel 2009 who had the shortest trisomies leading to VSD and AVSD (7.7 Mb and 10.0 Mb respectively). As can be seen in Figure 6B, these two regions overlap partly with the Dp3Tyb region reported in our study, but the trisomy in individual PM does not overlap with the *Ifnar1-Kcnj6* region identified by Liu et al. 2013. Taken together this suggests that several dosage-sensitive genes may contribute to CHDs, with potentially no single gene being absolutely required.

> There is a clear difference in phenotype that the authors discuss but rather underplay ("Dp1Tyb mice show AVSD with ventricular but not atrial shunting" -- "it is tempting to speculate that there are distinct mechanisms driving defects in the atrial and ventricular septa"). About 80% of Down\'s hearts with AVSD have the \"complete\" type, with shunting at atrial and ventricular level, whereas none of the hearts from mouse partial trisomies had this phenotype. The authors speculate that different mechanisms might act in the atrial and ventricular aspects of AV septal formation. If so, it could be considered that their models encompass only one of those two mechanisms.

We agree with the reviewers that Dp1Tyb models only one subtype of AVSD found in DS (with ventricular but not atrial shunting). As requested, we have added a sentence in the Discussion to clearly emphasize this point ("Dp1Tyb mice show AVSD with ventricular but not atrial shunting. Analysis of AVSD in people with DS showed that the most common subtype was a complete AVSD with both atrial and ventricular shunting and the next most common was AVSD with exclusive ventricular shunting similar to that seen in the Dp1Tyb mouse (Freeman et al., 2008)").

> There is no mention in the Discussion of mouse trisomy 16, which is not a good model of Down\'s-type defects for other reasons, but Ts16 hearts do have AVSD with shunting at the atrial level (Webb et al., (1999) Circ. Research 84:897-905), which is what is absent in the partial trisomy models studied here. Interestingly, Ts16 hearts do have deficiencies in DMP development.

As noted by the reviewers, Ts16 is not a good model for DS heart defects because it is trisomic for large numbers of genes that are not orthologous to genes on Hsa21. Indeed only 25% of Mmu16 is orthologous to Hsa21. Nonetheless this is an interesting mouse strain because it has defects in DMP development and shows AVSDs. We now refer to the analysis of Ts16 mice and the AVSD and DMP defects (Webb et al. 1999) in the Introduction (second paragraph) and Discussion (fourth paragraph).

> 2\) CHD are observed in 50% of people with Down Syndrome and usually necessitate cardiac surgery to avoid any late impairment. Here the results are limited to 14.5dpc embryos in which CHD and mainly AVSD are observed but little is described about the consequence of the CHD on perinatal viability. Kamp et al. (2010; PMID20511334) reported the identification of mouse congenital heart disease loci with most of them inducing perinatal lethality with CHD at birth. If the authors have data on the frequency of perinatal lethality and structural heart defects in the duplication carrier at birth, these should be included.

We agree this is an interesting point, but we do not have data on structural defects at birth. We estimate it would take at least 4 months to generate this. However, we have data on lethality of the duplication strains. At weaning we recover only 50% of the expected number of Dp1Tyb pups, and 75% of the expected number of Dp3Tyb pups. Given that in both strains around 25% of embryos have the most severe AVSD defects, this is the most likely cause of the lethality in Dp3Tyb, and explains part of the lethality in Dp1Tyb. The additional lethality in Dp1Tyb is due to other causes, including hydrocephalus. We have added data on the recovery of pups from each of the 7 strains in a new Table 1, present the data in the Results (subsection "A mouse genetic mapping panel for DS") and comment on it in the Discussion (first paragraph).

> 3\) It would be interesting to see a table with the number of individuals studied showing the different types of CHD compared to the total of embryos in the different mouse cohorts from the 7 duplication.

This data is shown in Table 2 (used to be Table 1).

> The authors should also discuss the variability of the CHD and AVSD phenotypes observed in wt control animals analysed from the different cohorts of mice. For example, the wt in Dp5Tyb and DP6Tyb or Ts1Rhr showed almost 20% of CHD compared to Dp9Tyb (5%?) Dp2Tyb and Dp3Tyb (10%?). What are the origins of such discrepancies in wt cohorts? A comparison of the CHD in wild-type individuals from the different cohorts, presented as a supplementary table, would add value to the analysis.

Again, this data is shown in Table 2 (used to be Table 1), with the numbers of embryos showing specific types of defects shown against each of the 7 strains, for both WT and mutant embryos.

For convenience, the Table below shows a summary of all defects found in the WT embryos from all 7 strains together.

**DefectNumber of embryos% embryos**ASD21.2%VSD2012%OFT+VSD31.8%AVSD+VSD21.2%Total defects2716%**Total number of WT embryos**164100%

We can see that the incidence of AVSDs in the WT embryos was very low (1.2%) and the most prevalent defect was a VSD (seen in 15.2%). These VSDs were generally very small and most likely represent slight developmental delay -- developmental timing could vary between litters, giving the apparent differences in defects between strains.

> 4\) The authors have done their analysis after 5 backcrosses on the C57BL/6JNimr genetic background. Could they assess if this level is sufficient in this particular situation? The presence of 2 copies of the 129S8 allele on the duplicated fragment versus the B6 allele may influence the outcome of the study (and may also explain the heterogeneity of the control littermates). Thus it would be interesting to check what is the real contribution of the B6 and 129 alleles, at least for the trisomic regions in the different models.

All the analysis was carried out with embryos that had been backcrossed at least for 5 generations into B6, but in some cases much more. Specifically, Dp1Tyb was analyzed after backcrossing to C57BL/6JNimr for 6-9 generations (N6-N9), Dp2Tyb at N5, Dp3Tyb at N8, Dp4Tyb at N5-N7, Dp5Tyb at N5, Dp6Tyb at N5-N11, Dp9Tyb at N11 and Ts1Rhr at N11-N12. Note that the strains showing significant CHDs were analyzed at N6-N9 (Dp1Tyb) and N8 (Dp3Tyb). This information has been added to the Materials and methods (subsection "Mice", last paragraph).

The reviewers ask if this level of backcrossing is sufficient and if the phenotype can be affected by the presence of 129P2 (not 129S8) alleles at the duplication. These are interesting issues but we are not able to address them directly. The first would require us to repeat the analysis at different backcross generations, which we have not done. We can point to our earlier study with Tc1 mice where we found the frequency of CHDs after N2 backcross to B6 was higher than that found in embryos on a 129xB6 F1 background (Dunlevy 2010), implying that more backcrossing to B6 makes the phenotype stronger. In the studies reported here the backcrossing was much more extensive (N6-N9 for Dp1Tyb, N8 for Dp3Tyb), but we don't know if the phenotype would get even stronger with further backcrosses.

Regarding the contribution of the 129P2 alleles at the duplication, again we cannot judge this. The strains were all generated on a 129P2 background and then backcrossed. Such backcrossing dilutes away 129P2 alleles everywhere in the genome except around the site of the duplication. The sequences nearest the duplication will always be 129P2-derived, and the extent of remaining 129P2 DNA around this point is variable will depend stochastically on the location of meiotic crossovers. The only way to do a direct comparison would be to generate the duplications in both 129 and B6 ES cells and compare the resulting mice, something we have not done.

Finally, the reviewers ask if the extent of backcrossing could account for the difference in the incidence of defects recorded in WT mice. We don't believe this can explain the variation in the frequency of defects. For example higher levels of defects were found in the WT mice from the Dp5Tyb (N5) and Ts1Rhr (N11-N12) strains and no defects at all in WT mice in Dp4Tyb (N5-N7) mice. So there appears to be no correlation between extent of backcross and incidence of defects in WT mice. Instead we think the large majority of defects seen in WT mice are very small VSDs, which are caused by slight developmental delay (see above).

> 5\) An important point is whether by crossing strains Dp4Tyb, Dp5Tyb and Dp6Tyb, the CHD can be reconstituted to narrow further the key genetic contributions.

We agree that this is certainly interesting, and we are in the process of doing this, in order to get a better idea of where the key dosage-sensitive genes lie. These data will be used in a follow up paper and we estimate that it will take at least another 12 months before we would have sufficient data on heart structure in crosses of Dp4Tyb x Dp5Tyb, Dp4Tyb x Dp6Tyb and Dp5Tyb x Dp6Tyb (we need to analyse around 100 embryos from each cross). Of course it might turn out that all three intervals are needed, in which case we might need to make a triple Dp4Tyb x Dp5Tyb x Dp6Tyb cross to reconstitute the phenotype, which would take longer still. While interesting, this would give more information on which intervals contain dosage-sensitive genes, but would not identify the genes themselves. Thus in our view it would only be an incremental advance over what is presented in the current manuscript, and does not warrant the very long delay that would be incurred by waiting for this data.

> Incomplete penetrance is commonplace in CHD and the finding that two genes require three copies to produce CHD in these models is intriguing in this context and merits further discussion.

We have added text to the Discussion about incomplete penetrance of CHD seen in both humans with DS and in the mouse models (first paragraph). However, we are not sure why the reviewers think a requirement for 2 dosage-sensitive genes to be present in 3 copies would contribute to incomplete penetrance.

> 6\) The conclusions about which regions of Dp1Tyb are required in three copies to induce Downs-type heart defects rely wholly on comparisons between some very small numbers of abnormal hearts, which are usefully summarized in Table 1. Hearts from Ts1Rhr and Dp5Tyb each had 2 AVSD (of 21 and 20 examined respectively), which is undoubtedly statistically different from the incidences in Dp1Tyb and Dp3Tyb, but it is difficult to say with certainty that there is no effect in Ts1Rhr and Dp5Tyb, particularly given that there was only 1 AVSD observed in about 170 wild type hearts. There could be a weak combinatorial effect of a number of genes throughout the region. The authors should be more cautious in the wording of their conclusions.

We agree with the reviewers that it is certainly possible that there is a weak phenotype in Ts1Rhr and Dp5Tyb, which does not reach significance in these studies. As pointed out, each of these two strains showed 2 embryos with AVSD (out of 21 and 20 analyzed respectively). When the incidence of AVSD in these strains is compared to their littermate WT controls, the incidence in the mutants is not significantly different (p = 0.5). We estimate that if these strains have an incidence of AVSD at 10%, we would need to analyze around 60 mutant and 60 wt embryos to see a significance difference at p \< 0.05. We have added text to point out the possibility of a weak phenotype in these two strains (Discussion, second paragraph).

> \[One of the AVSD in Dp5Tyb did not have an ASD or VSD, an outlier which goes without explanation or mention\].

We thank the reviewers for pointing this out. We went back to look at the original data from this embryo again and confirmed that it did indeed have an AVSD, but it also had a very small perimembranous VSD, so it is not an outlier. We have reclassified it in Table 2 under "VSD+AVSD".

> 7\) For completeness, it would be useful to generate Isl1Cre lineage marked Dp1Tyb hearts, as well as the Isl1nLacZ expression (this is incorrectly termed \"lineage\" in the subsection "The DMP is present and largely unaffected in the Dp1Tyb mouse model for DS") marked hearts. It would be informative to show these data at E14.5, in definitively AVSD hearts.

We do not have data from such a cross. We estimate that to breed the relevant mice and analyse the embryos could take 9-12 months. However in our view this would not add much to the paper.

The reviewers have asked for this because at E14.5 Isl1 is no longer expressed in the DMP, and so cannot be visualized using LacZ expression from the Isl1nLacZ reporter. The Isl1Cre x R26RLacZ cross referred to by the reviewers is a fate reporter and so LacZ expression persists in the DMP at E14.5. However we do not need to cross this to the Dp1Tyb in order to identify the DMP. We can readily identify the DMP in the 3D HREM data at E14.5 using morphological criteria, in part because we have previously used the Isl1Cre x R26RLacZ fate reporter in wild-type embryos to locate this tissue. Crossing it to Dp1Tyb, would make the study more complete, but, in our view, would not add any further insights into the pathology.

We have corrected the incorrect reference to lineage (subsection "Development of the DMP").
